| Literature DB >> 23843786 |
Bennasr Hmed1, Hammami Turky Serria, Zeghal Khaled Mounir.
Abstract
Several peptides contained in scorpion fluids showed diverse array of biological activities with high specificities to their targeted sites. Many investigations outlined their potent effects against microbes and showed their potential to modulate various biological mechanisms that are involved in immune, nervous, cardiovascular, and neoplastic diseases. Because of their important structural and functional diversity, it is projected that scorpion-derived peptides could be used to develop new specific drugs. This review summarizes relevant findings improving their use as valuable tools for new drugs development.Entities:
Year: 2013 PMID: 23843786 PMCID: PMC3697785 DOI: 10.1155/2013/958797
Source DB: PubMed Journal: J Toxicol ISSN: 1687-8191
List of various families of polypeptides isolated from scorpion venom and hemolymph.
| Family | Subfamilies | Targeted site |
|---|---|---|
| Peptides acting on Na+ channels | ||
|
| ||
|
| ||
|
|
| Site 3 |
|
| ||
|
| ||
|
|
| Site 4 |
|
| ||
|
| ||
| Peptides acting on K+ channels | ||
|
| ||
|
| In conjunction with the appropriate targeted site. | Kv1.x channels |
| KCa1.1 | ||
| KCa2.x | ||
| KCa3.1 | ||
| Kv11.x | ||
|
| Nd | Nd |
|
| Nd | Kv11.x |
|
| Nd | Kv1.x |
|
| ||
| Peptides acting on Cl− channels | ||
|
| ||
| Nd [ | Nd | Ca2+-activated Cl− channels (CFTR) |
|
| ||
| Peptides acting on Ca2+ channels | ||
|
| ||
| Nd [ | Nd | Ryanodine receptor |
|
| ||
| Peptides with free cysteine residues | ||
|
| ||
| BPPs [ | Nd | Nd |
| AMPs [ | Nd | Membrane phospholipids |
|
| ||
| Peptides with enzymatic activities | ||
|
| ||
| PLAs2 [ | Nd | Nd |
| Hyaluronidases [ | Nd | Nd |
List of antibacterial peptides isolated from scorpions.
| Scorpion | Fraction | Pathogens | Dose | Reference |
|---|---|---|---|---|
|
| Mucroporin |
| 50 | |
|
| 25 |
[ | ||
| Mucroporin-M1 |
| 25 | ||
|
| 5 | |||
|
| ||||
|
| Bmkn2 |
| 6.25 | |
|
| >100 | |||
| Kn2-7 |
| 6.25 | [ | |
|
| >100 | |||
|
| ||||
|
| Meucin-24, 25 |
| — | [ |
| Meucin-18 |
| 0.25 | ||
|
| 10.9 |
[ | ||
| Meucin-13 |
| 0.25 | ||
|
| >50 | |||
|
| ||||
|
| Bmkb1 |
| 16 | |
|
| 18.1 |
[ | ||
| Bmkn2 |
| 0.6 | ||
|
| 1.5 | |||
|
| ||||
|
| Ctriporin |
| 10 | |
|
| 5 | [ | ||
|
| 5 | |||
|
| ||||
|
| Parabutoporin |
| 1.6 |
[ |
|
| 3.1 | |||
|
| ||||
|
| Imcroporin |
| 20 | |
|
| 20 | [ | ||
|
| 50 | |||
|
| ||||
|
| IsCT |
| 0.7 | |
|
| 3.3 | [ | ||
| IsCT2 |
| 0.7 | ||
|
| 3.4 | |||
| [A6]-IsCT |
| >64 | ||
|
| 64 | |||
| [L6]-IsCT |
| 64 | ||
|
| 16 | |||
| [K7]-IsCT |
| 1 |
[ | |
|
| 2 | |||
| [L6,K11]-IsCT |
| 2 | ||
|
| 2 | |||
| [K7,P8,K11]-IsCT |
| 2 | ||
|
| 2 | |||
|
| ||||
|
| Opistoporin-1 |
| 1.3–25 | |
|
| >50 |
[ | ||
| Opistorporin-2 | — | — | ||
|
| ||||
|
| Androctonin |
| 0.5–1.5 |
[ |
|
| 0.25–0.6 | |||
|
| 1.5–3 |
[ | ||
|
| 3–6 | |||
|
| ||||
|
| Pandinin-1 |
| 1.3–5.2 | |
|
| >20.8 |
[ | ||
| Pandinin-2 |
| 2.4–4.8 | ||
|
| 19.1–38.2 | |||
|
| 1 |
[ | ||
| Scorpine |
| 10 | ||
|
| 0.7 | |||
|
| ||||
|
| Hadrurin |
| <10 |
[ |
|
| >40 | |||
|
| ||||
|
| HgeScplp1 |
| 0.2–0.5 | |
|
| 0.2–0.5 | |||
| Hge |
| 0.2–0.5 |
[ | |
|
| >0.5 | |||
| Hge36 |
| >0.5 | ||
|
| >0.5 | |||
|
| ||||
|
| Noxiustoxin |
| 0.7 | [ |
|
| ||||
|
| StCT1 |
| 12.5 |
[ |
|
| 100 | |||
| StCT2 |
| 6.25 | [ | |
|
| ||||
|
| VmCT1 | — | 5–25 |
[ |
| VmCT2 | — | 10–20 | ||
|
| ||||
|
| HS-1 |
| — | |
|
| — | [ | ||
|
| — | |||
|
| ||||
|
| HsAP2, 3, 4 | — | — | [ |
|
| ||||
|
| Whole venom | — | — | [ |
The dose represents the MIC, the EC50% (+), or the EC100% (#) of the polypeptide, or LD100% (lethal dose ∗) of the polypeptide.
List of chosen antiviral peptides originating from scorpions.
| scorpion | Fraction | Viruses | Dose | Reference |
|---|---|---|---|---|
|
| Mucroporin | HIV-1 | — | [ |
| HBV | ||||
| Mucroporin-M1 | HIV-1 | — | ||
| HBV | 87 | |||
| Mucroporin-S1 | HIV-1 | >100 | ||
|
| Bmkn2 | HIV-1 | — | |
| Kn2-7 | HIV-1 | 2.76 | ||
|
| Ctriporin | HBV | — | |
|
| Hp1090 | HCV | 5 | |
| Mucroporin-M1 | Measles | 3.52 | ||
| SARS-CoV | 7.12 | |||
| H5N1 | 1.03 |
The dose represents the MIC, the EC50% (+), or the EC100% (#) of the polypeptide.
Figure 1Schematic proposed models for scorpion toxins use in cancer and metastasis therapy. Scorpion toxins are dotted with high specificity to targeted specific cells receptors enabling them to be potent candidate for drugs carrier. (a) Radioactive iodine delivery into brain gliomas using chlorotoxin as a guider to target cancerous cells. (b) The chlorotoxin triggers gene transfection for cancer cells therapy. (c) Direct effect of pertussis toxin in abolishing metastasis. It did inhibit migration (evasion) through blocking the transduction signal of the lysophosphatidic acid pathway.
Summary of the modus operandi of some scorpion derivatives with potential therapeutic use.
| Peptides | Origin | Biological effects |
|---|---|---|
| Immune diseases | ||
| Charybdotoxin [ |
| Blockade of shaker potassium channels (Kv1.3.) which suppresses lymphocytes proliferation and IL2 production. |
| Parabutoporin [ |
| Activation of the Rac receptor coupled to G protein, and inhibiting NADPH/oxidase complex function. The cumulus of these actions enhances exocytosis and chemotaxis and prevents superoxide production. |
| Fraction 1 [ |
| Stimulating lymphocytes proliferation. |
| Total venom [ |
| Lymphocytes proliferation enhancement. |
|
| ||
| Cardiovascular diseases | ||
|
|
| PAFR stimulation (aggregating factor) |
| Charybdotoxin [ |
| Blockade of voltage and Ca2+-activated potassium channels, decreasing prothrombinase activity and phosphatidylserine exposition (aggregating factor). |
| SVAP [ |
| Increasing PGI2 production/altering pro- and anti inflammatory compounds release, probably from white blood cells. |
| Bpps (Bppk12) [ |
| Inhibiting the downregulation of the bradykinin (vasodilatator) and the angiotensin II (vasoconstrictor) synthesis. |
| Hypotensins [ |
| Inhibiting the downregulation of the bradykinin and enhancing NO release. |
|
| ||
| Neurological diseases | ||
| Various [ |
| Interaction with adrenergic and cholinergic receptors. |
| K+ channels blockers [ |
| Blockade of potassium current which prevents symptoms and signs in multiple sclerosis. |
| Whole venom [ |
| Inhibition of the voltage-sensitive sodium channels. |
|
| ||
| Cancer | ||
| Chlorotoxin [ |
| Carrying gene transfecting-nanovecteors to their targeted cancer cells. |
| AmmTx3 [ |
| Blockade of hERGK+ channels involved in tumoral cells activities. |
| BmHYA1 [ |
| Modulation of cell cycle, apoptosis and invasion. |
| PESV [ |
| Enhances the immune sentinel against tumors. |
|
| ||
| Osteoporosis | ||
| Whole venom [ |
| Stimulation of osteoclast activity and mineral deposits and modulation the release of osteoporosis regulating factors (antiosteoporosis). |
| KTXs [ |
| Blockade of Kv1.3 channels which reduce inflammatory bone resorption. |
Figure 2Schematic model representing the process in need to distillate scorpion derivatives with potential clinical use.